Double-Blind Placebo-Controlled Comparison of Enoximone and Dobutamine Infusions in Patients With Moderate to Severe Chronic Heart Failure

Congestive Heart Failure

Volumn 16, Issue 6, 2010, Pages 265-270

  Bader, Feras M ^a   Gilbert, Edward M ^a   Mehta, Neal A ^a   Bristow, Michael R ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; DIURETIC AGENT; DOBUTAMINE; ENOXIMONE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HEADACHE; HEART FAILURE; HEART INDEX; HEMODYNAMIC PARAMETERS; HUMAN; LOADING DRUG DOSE; LUNG CAPILLARY PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ADULT; AGED; AGED, 80 AND OVER; CARDIOTONIC AGENTS; CHRONIC DISEASE; CORONARY CIRCULATION; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLIC GMP-DEPENDENT PROTEIN KINASES; DISEASE PROGRESSION; DOBUTAMINE; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY, AMBULATORY; ENOXIMONE; FEMALE; HEALTH STATUS INDICATORS; HEMODYNAMICS; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PULMONARY WEDGE PRESSURE; STATISTICS AS TOPIC; STROKE VOLUME; SYMPATHOMIMETICS; VENTRICULAR FUNCTION, LEFT;

EID: 78649474760     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2010.00185.x     Document Type: Article

References (26)

1. Stevenson LW, Massie BM, Francis GS. Optimizing therapy for complex or refractory heart failure: a management algorithm. Am Heart J. 1998;135(6 Pt 2 suppl):S293-S309.
2. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000;343(4):246-253.
3. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991;325(21):1468-1475.
4. Krell MJ, Kline EM, Bates ER, et al. Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure. Am Heart J. 1986;112(4):787-791.
5. Uretsky BF, Jessup M, Konstam MA, et al. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group. Circulation. 1990;82(3):774-780.
6. Movsesian MA, Smith CJ, Krall J, et al. Sarcoplasmic reticulum-associated cyclic adenosine 5'-monophosphate phosphodiesterase activity in normal and failing human hearts. J Clin Invest. 1991;88(1):15-19.
7. Dage RC, Okerholm RA. Pharmacology and pharmacokinetics of enoximone. Cardiology. 1990;77(suppl 3):2-13; discussion 27-33.
8. Movsesian MA. PDE3 inhibition in dilated cardiomyopathy: reasons to reconsider. J Card Fail. 2003;9(6):475-480.
9. Lowes BD, Simon MA, Tsvetkova TO, Bristow MR. Inotropes in the beta-blocker era. Clin Cardiol. 2000;23(3 suppl):III11-III16.
10. Lowes BD, Tsvetkova T, Eichhorn EJ, et al. Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol. 2001;81(2-3):141-149.
11. Metra M, Nodari S, D'Aloia A, et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol. 2002;40(7):1248-1258.
12. Shakar SF, Abraham WT, Gilbert EM, et al. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol. 1998;31(6):1336-1340.
13. Kumar A, Choudhary G, Antonio C, et al. Carvedilol titration in patients with congestive heart failure receiving inotropic therapy. Am Heart J. 2001;142(3):512-515.
14. Hauptman PJ, Woods D, Prirzker MR. Novel use of a short-acting intravenous beta blocker in combination with inotropic therapy as a bridge to chronic oral beta blockade in patients with advanced heart failure. Clin Cardiol. 2002;25(5):247-249.
15. Gilbert EM, Hershberger RE, Wiechmann RJ, et al. Pharmacologic and hemodynamic effects of combined beta-agonist stimulation and phosphodiesterase inhibition in the failing human heart. Chest. 1995;108(6):1524-1532.
16. Thuillez C, Richard C, Teboul JL, et al. Arterial hemodynamics and cardiac effects of enoximone, dobutamine, and their combination in severe heart failure. Am Heart J. 1993;125(3):799-808.
17. Pratt CM, Moye LA. The Cardiac Arrhythmia Suppression Trial: background, interim results and implications. Am J Cardiol. 1990;65(4):20B-29B.
18. Erbel R, Meyer J, Diefenbach C, et al. A dose-response study of intravenous enoximone in congestive heart failure. Am J Cardiol. 1987;60(5):31C-36C.
19. Likoff MJ, Ulrich S, Hakki A, Iskandrian AS. Comparison of acute hemodynamic response to dobutamine and intravenous MDL 17, 043 (enoximone) in severe congestive heart failure secondary to ischemic cardiomyopathy or idiopathic dilated cardiomyopathy. Am J Cardiol. 1986;57(15):1328-1334.
20. Dec GW, Fifer MA, Herrmann HC, et al. Long-term outcome of enoximone therapy in patients with refractory heart failure. Am Heart J. 1993;125(2 Pt 1):423-429.
21. Installe E, Gonzalez M, Jacquemart JL, et al. Comparative effects on hemodynamics of enoximone (MDL 17, 043), dobutamine and nitroprusside in severe congestive heart failure. Am J Cardiol. 1987;60(5):46C-52C.
22. Cuffe MS, Califf RM, Adams KF, et al. Rationale and design of the OPTIME CHF trial: outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure. Am Heart J. 2000;139(1 Pt 1):15-22.
23. Lowes BD, Higginbotham M, Petrovich L, et al. Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group. J Am Coll Cardiol. 2000;36(2):501-508.
24. Metra M, Eichhorn E, Abraham WT, et al. Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. Eur Heart J. 2009;30(24):3015-3026.
25. O'Connell JB, Gilbert EM, Renlund DG, Bristow MR. Enoximone as a bridge to heart transplantation: the Utah experience. J Heart Lung Transplant. 1991;10(3):477-481.
26. Narahara KA. Oral enoximone therapy in chronic heart failure: a placebo-controlled randomized trial. The Western Enoximone Study Group. Am Heart J. 1991;121(5):1471-1479.